Oorsprong van het eerstegraads netwerk van Marguerite Hutchinson
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA.
6
| Subsidiary | Miscellaneous Commercial Services | 6 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Marguerite Hutchinson via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Treasurer | |
INTEL CORPORATION | Semiconductors | Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Director/Board Member | |
CTI BIOPHARMA CORP. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
KINEMED INC | Miscellaneous Commercial Services | Director/Board Member | |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
CODEXIS, INC. | Chemicals: Specialty | Director/Board Member | |
PORTOLA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Roche Diagnostics GmbH
Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
New York University | College/University | Undergraduate Degree | |
University of California, Berkeley | College/University | Undergraduate Degree Doctorate Degree | |
University of Louisville | College/University | Doctorate Degree | |
Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
Max-Planck-Institute for Molecular Genetics | College/University | Chief Tech/Sci/R&D Officer | |
Enterome SA
Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member | |
Kellogg School of Management | College/University | Masters Business Admin | |
Vanderbilt University School of Medicine | College/University | Doctorate Degree | |
CYTOMX THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
VAXCYTE, INC. | Biotechnology | Director/Board Member | |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Chairman Director/Board Member | |
Apollomics, Inc. (United States)
Apollomics, Inc. (United States) BiotechnologyHealth Technology Apollomics, Inc. operates as a sciences oncology company. It is a biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company was founded by Sanjeev Gurunath Redkar and Guo-Liang Yu on May 21, 2015 and is headquartered in Foster City, CA. | Biotechnology | Chief Tech/Sci/R&D Officer | |
CuraSen Therapeutics, Inc.
CuraSen Therapeutics, Inc. BiotechnologyHealth Technology CuraSen Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapies to treat neurodegenerative diseases, including parkinson, alzheimer, and less common neurodegenerative disorders. The company was founded by Mehrdad Shamloo, Robert Booth, Anthony Ford, and Kathleen Sereda in 2018 and is headquartered in San Mateo, CA. | Biotechnology | Founder | |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member Chairman | |
ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
TRex Bio Ltd.
TRex Bio Ltd. BiotechnologyHealth Technology TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian. | Biotechnology | Director/Board Member | |
ALX ONCOLOGY HOLDINGS INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
IO BIOTECH, INC. | Biotechnology | Chairman Director/Board Member | |
Opna Bio SA
Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Pharmaceuticals: Generic | Founder |
Statistieken
Internationaal
Verenigde Staten | 30 |
Duitsland | 4 |
Denemarken | 3 |
Frankrijk | 2 |
Kaaimaneilanden | 2 |
Sectoraal
Health Technology | 28 |
Consumer Services | 8 |
Commercial Services | 3 |
Electronic Technology | 2 |
Process Industries | 2 |
Operationeel
Director/Board Member | 20 |
Chief Tech/Sci/R&D Officer | 11 |
Independent Dir/Board Member | 7 |
Corporate Officer/Principal | 7 |
Doctorate Degree | 4 |
Sterkste connecties
Insiders | |
---|---|
K. Hirth | 18 |
Kathleen Glaub | 13 |
Glenn Michelson | 9 |
Gideon E. Bollag | 6 |
Athanasios Tsiatis | 4 |
Chao Zhang | 1 |
- Beurs
- Insiders
- Marguerite Hutchinson
- Bedrijfsconnecties